Metabolic and Bariatric Surgery Outperforms GLP-1 Receptor Agonists for Weight Loss, Glycemic Control, and Cost
Background
Obesity management has seen a significant shift with the rise of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), offering pharmacological alternatives to traditional interventions. Historically, metabolic and bariatric surgery (MBS) has been considered the most effective long-term treatment for severe obesity, demonstrating superior and sustained weight loss and improvements in metabolic comorbidities like type 2 diabetes. However, a direct, updated comparison of the effectiveness and cost-efficiency between these two major therapeutic strategies has been lacking, leaving a critical gap in guiding patient and clinician decision-making regarding optimal treatment pathways. This meta-analysis addresses this by integrating the latest evidence to provide a comprehensive comparative outcome assessment.
Study Design
Researchers conducted a systematic review and meta-analysis across five databases, including 11 studies with a total of 14,548 patients, to compare outcomes between GLP-1 RAs and MBS. The primary endpoint was the difference in percentage of total weight loss (%TWL). Secondary outcomes included differences in glycated hemoglobin (HbA1c), body mass index (BMI), and patient out-of-pocket (OOP) costs. A random-effects model was employed to calculate pooled odds ratios (OR) and mean differences (MD) with 95% confidence intervals (CI). The GLP-1 group comprised 7435 patients, while the MBS group accounted for the remainder.
Results
The meta-analysis revealed that GLP-1 RAs resulted in a significantly lower %TWL compared to MBS, with a mean difference of -19.98% (P < .001). This reduced weight loss was sustained, showing a mean difference of -23.69% at 12 months and -19.57% at 24 months. Similarly, BMI reduction was also significantly lower in the GLP-1 RA group, with a mean difference of -7.17 (P < .001). > Glycemic control, as measured by HbA1c reduction, was also inferior with GLP-1 RAs, demonstrating a mean difference of -0.99% (P < .001) compared to MBS. A subgroup analysis comparing liraglutide 1.2 mg daily to Roux-en-Y gastric bypass showed an even greater disparity in HbA1c reduction, with a mean difference of -1.62%. Furthermore, mean OOP costs at 24 months were significantly higher for the GLP-1 group, with a mean difference of +$749.38 (P < .001). Baseline BMI was lower in GLP-1 RA patients (MD = -1.23; P = .002), but age and sex distribution were similar.
Why It Matters
This comprehensive meta-analysis provides critical evidence affirming the superior efficacy of metabolic and bariatric surgery (MBS) over GLP-1 receptor agonists (GLP-1 RAs) for long-term weight loss, BMI reduction, and glycemic control. For individuals seeking the most robust and sustained outcomes in obesity and type 2 diabetes management, MBS remains the gold standard. While GLP-1 RAs offer a valuable pharmacological option, particularly for those unwilling or unable to undergo surgery, they do not match the profound and durable metabolic improvements seen with surgical intervention. Clinically, this suggests GLP-1 RAs may best serve as a complementary strategy within a multidisciplinary approach, potentially as a bridge to surgery, for managing weight regain post-surgery, or for patients with lower BMIs where surgery is not indicated. This data also highlights the significant long-term cost implications, with GLP-1 RAs incurring higher patient OOP expenses over 24 months.